Calliditas Interim Report January – September 2023
The Lancet publication of full Phase 3 data setIn August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published in The Lancet and we are looking forward to a potential full approval of TARPEYO for treatment of IgA Nephropathy, for which the PDUFA date is December 20, 2023. Financial Summary of Q3 2023 July 1 – September 30, 2023 · Net sales amounted to SEK 294.6 million, of which TARPEYO® net sales amounted to SEK 283.6 million, for the three months ended September 30, 2023. For the three months ended September 30, 2022, net sales amounted